000			06051cam a2200433Ii 4500
001			96113
003			ES-MaUEC
005			20230102112739.0
006			m o d
007			cr cnu|||unuuu
008			170602s2017 sz ob 001 0 eng d
020			_a3319546414
020			_a3319546430 _q(electronic bk.)
020			_a9783319546414
020			_a9783319546438 _q(electronic bk.)
020			_z9783319546414
040			_aN$T _cN$T _dN$T _dEBLCP _dGW5XE _dYDX _dAZU _dUPM _dOCLCF _dCOO _dVT2 _dOCLCQ _dUAB _dES-MaUEC _bspa
050		4	_aRM340 _b2017 EB
245	0	0	_aOral anticoagulation therapy : _bcases and clinical correlation _cKathryn Kiser, editor.
264		1	_aCham, Switzerland _bSpringer International Publishing _c2017
264		4	_c2017
300			_a1 recurso en línea
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF
504			_aIncluye referencias bibliográficas e índice
505	0		_aPart I: Introduction; Chapter 1: Introduction; Part II: Atrial Fibrillation; Chapter 2: CHA2DS2-VASc and HAS-BLED Risk Stratification Tools; Case Introduction; Case Discussion; Risk of Stroke; Risk of Bleeding; How Does a Clinician Choose Among the Various Agents for Stroke Prevention?; Key Points; Self-Assessment Questions; References; Chapter 3: Male with Priority of Ischemic Stroke Reduction; Discussion; Key Points; Self-Assessment Questions; References; Chapter 4: Choosing an Anticoagulant in an Elderly Patient; Case Introduction; Case Discussion; Key Points.
505	8		_aCase Discussion Key Points; Self-Assessment Questions; References; Chapter 13: Patient with Concomitant Mitral Valve Stenosis; Case Introduction; Case Discussion; Key Points; Self-Assessment Questions; References; Chapter 14: Patient with Concomitant Aortic Valve Stenosis; Case Introduction; Case Discussion; Key Points; Self Assessment Questions; References; Part III: Warfarin Management; Chapter 15: Best Practice for Switching Stable Warfarin Patients; Case Introduction; Case Discussion; FDA-Approved Indications for Use; Comparison of DOACs with Warfarin.
505	8		_aChapter 10: Oral Anticoagulants in Patients with Variable Renal Function Case Introduction; Case Discussion; Background; Considerations for DOAC Management in Variable Renal Function; Upon Admission; Case Continuation; Prior to Discharge; Case Continuation; During Hospitalization Follow-up; The Outcome; Key Points; Self-Assessment Questions; References; Chapter 11: Patient with Concomitant Stable Coronary Artery Disease; Case Discussion; Key Points; Self-Assessment Questions; References; Chapter 12: Patient with Concomitant Acute Venous Thromboembolism; Case Introduction.
505	8		_aSelf-Assessment QuestionsReferences; Chapter 5: Patient with Prior History of GI Hemorrhage; Case Introduction; Case Discussion; Key Points; Self-Assessment Questions; References; Chapter 6: Patients with a History of Intracranial Hemorrhage; Case Introduction; Key Points; Self-Assessment Questions; References; Chapter 7: Concerns with Anticoagulant Adherence; Key Points; Self-Assessment Questions; References; Chapter 8: Oral Anticoagulants in Stable Moderate Chronic Kidney Disease; Case Introduction; Case Discussion; Background.
505	8		_aWhat Factors Should be Considered When Selecting an Oral Anticoagulant for Patients with Stable Moderate Renal Function? The Outcome; Key Points; Self-Assessment Questions; References; Chapter 9: Oral Anticoagulants in Severe Renal Dysfunction; Case Discussion; What Is this Patient's Risk of Stroke and Bleeding?; What Is the Evidence for Use of Direct Oral Anticoagulants (DOACs) in Severe CKD?; What Are Considerations When Using Warfarin in CKD?; What Is the Best Anticoagulation Plan for this Patient?; Key Points; Self-Assessment Questions; References.
520	3		_aGiven the amount and complexity of information surrounding the the target specific oral anticoagulants a lengthy didactic educational format has the potential to be overwhelming to the reader and difficult to translate and apply to direct patient care. The proposed book will educate clinicians utilizing a series of clinical cases to simultaneously develop the readers' knowledge base, problem-solving skills, and practically apply their new knowledge to a variety of clinical situations. These will be short focused case presentations that provide critical information and pose questions to the reader at key points in the decision making process. The cases will be relevant to what clinicians will encounter not only on a daily basis, but also reflective of scenarios that clinicians will not encounter regularly, but that they will have to act upon (e.g. a bleeding patient, patient scheduled for elective or emergent procedure, patient with changing renal function, patient on drugs that have a plausible yet unstudied drug interaction with a target specific oral anticoagulant etc). Included in the case studies will be evidence-based discussions (with appropriate references) that provide immediate feedback on the different treatment alternatives that were offered. The case studies will be designed to instruct the reader how to select and effectively utilize the most appropriate agent for a given clinical scenario. They will focus on key features of the target specific oral anticoagulants, what they have in common, how they are unique from each other, as well as illustrating the clinical decision process one should take when selecting an agent or managing a patient already receiving one of the target specific oral agents.
650		7	_aAnticoagulantes _2embne _0(OCoLC)fst00810468 _0 _9144124
700	1		_aKiser, Kathryn, _eeditor literario
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-54643-8 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988			_aSpringer_Medicine_2017
998			_b02/2018 _dz _e- _zSI
999			_c96113 _d96113 _x1